MD13 is a potent MIF (macrophage migration inhibitory factor) Degrader (PROTAC™) (DC50 < 100 nM; Dmax = 92% after 6 h). MD13 comprises the cereblon ligand Pomalidomide (Cat. No. 6302) joined by a linker to a MIF inhibitor. MD13 reduces MIF levels, arrests cells at the G2/M phase and inhibits proliferation of A549 lung carcinoma cells. Growth of A549 cell 3D spheroids is also inhibited by MDF13.
Negative control MD15 (Cat.No. 7504) also available.
PROTAC™ is a registered trademark of Arvinas Operations, Inc., and is used under license.
Caractéristiques techniques
| Marque | Tocris Bioscience |
| Réf. B-LABO | BL-RE-125164 |
| Réf. fabricant | 18775476 |
| Nom chimique ou matériau | 8-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-(4-(7-hydroxy-2-oxo-2 H-benzo[e][1,3 ]oxazin-3(4 H)-yl)phenyl)octanamide |
|---|
| Quantité | 5 mg |
|---|
| Cible | Active Degraders |
|---|
| Formule moléculaire | C<sub>35</sub>H<sub>35</sub>N<sub>5</sub>O<sub>8</sub> |
|---|
| Pureté | 0.98 |
Une question, une configuration particulière ?
Contactez-nous pour un devis.